A similar study had also proved that dual therapy with ramucirumab and erlotinib could suppress EGFR-activating mutation allele count in EGFR-mutated, advanced NSCLC.40 Tracking temporal changes in TML and the frequencies of key driver gene mutations in individual patients could better delineate the dynamics of gene mutations during disease progression. Here, EGFR is linked to non-small cell lung carcinoma.